Aileron Therapeutics ALRN shares are trading lower on Monday after the company on Saturday announced clinical data from its ongoing Phase 1b trial of ALRN-6924.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. The company's lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers.
Aileron Therapeutics shares traded down 23.16% to $1.46 on Monday at the time of publication. The stock has a 52-week high of $2.47 and a 52-week low of 25 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.